Sign Up to like & get
recommendations!
0
Published in 2025 at "Pharmaceuticals"
DOI: 10.3390/ph18081110
Abstract: Background/Objectives: Oncogenic KRAS drives ~30% of solid tumours, yet the only approved G12C-specific drugs benefit ≈ 13% of KRAS-mutant patients, leaving a major clinical gap. We sought mutation-agnostic natural ligands from Ziziphus lotus, whose stereochemically…
read more here.
Keywords:
molecular dynamics;
mutation agnostic;
ziziphus lotus;
switch groove ... See more keywords